Effects of Tibolone Combined with Zoledronic Acid on Bone Density, Bone Metabolism, and Pain in Postmenopausal Patients with Osteoporosis

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2024 Aug 8

PMID 39114689

Authors

San-Bao Zou

Zhen-Hua Zeng

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the efficacy and safety of tibolone combined with zoledronic acid in the treatment of postmenopausal osteoporosis (PMO).

Methods: We conducted a retrospective analysis of 121 PMO patients from March 2019 to July 2021. Patients were divided into two groups based on treatment regimen: an observation group (n=62) receiving zoledronic acid combined with tibolone and a control group (n=59) receiving tibolone monotherapy. We evaluated and compared therapeutic efficacy, bone mineral density, bone metabolism markers (osteocalcin, serum C-terminal telopeptide of type I collagen, and bone alkaline phosphatase), pain, knee joint function, incidence of fragility fractures, and adverse reactions. Logistic regression analysis was used to evaluate risk factors affecting treatment efficacy.

Results: The observation group showed a significantly higher therapeutic effect (96.77%) compared to the control group (83.05%), and a lower incidence of fragility fractures (P=0.012). Before treatment, there were no significant differences in bone mineral density, bone metabolism markers, pain status, or knee function between the two groups (all P>0.05). However, after treatment, evaluations showed marked improvements in these parameters in both groups, with more significant enhancements observed in the observation group (all P<0.001). The incidence of adverse reactions did not significantly differ between the groups (20.97% vs 13.56%, P=0.282). Logistic regression analysis identified the use of tibolone combined with zoledronic acid as a protective factor for effective treatment.

Conclusions: Tibolone combined with zoledronic acid significantly increases bone mineral density, improves bone metabolism, and reduces pain in PMO patients, with a safety profile comparable to that of monotherapy. This regimen should be considered for clinical use in treating PMO.

References

Kim J, Kang S, Nam K, Rhee S, Won J, Han H . Retrograde intramedullary nailing for distal femur fracture with osteoporosis. Clin Orthop Surg. 2012; 4(4):307-12. PMC: 3504696. DOI: 10.4055/cios.2012.4.4.307. View

Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020; 26(Suppl 1):1-46. DOI: 10.4158/GL-2020-0524SUPPL. View

Duralde E, Sobel T, Manson J . Management of perimenopausal and menopausal symptoms. BMJ. 2023; 382:e072612. DOI: 10.1136/bmj-2022-072612. View

Liu G, Wang Z, Liu L, Zhang B, Miao Y, Yu S . A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis. J Cell Biochem. 2017; 119(6):4469-4481. DOI: 10.1002/jcb.26550. View

Del Rio J, Molina S, Hidalgo-Lanussa O, Garcia-Segura L, Barreto G . Tibolone as Hormonal Therapy and Neuroprotective Agent. Trends Endocrinol Metab. 2020; 31(10):742-759. DOI: 10.1016/j.tem.2020.04.007. View

Castrejon-Delgado L, Castelan-Martinez O, Clark P, Garduno-Espinosa J, Mendoza-Nunez V, Sanchez-Rodriguez M . Effect of Tibolone on Bone Mineral Density in Postmenopausal Women: Systematic Review and Meta-Analysis. Biology (Basel). 2021; 10(3). PMC: 8000366. DOI: 10.3390/biology10030211. View

Muhammad A, Mada S, Malami I, Forcados G, Erukainure O, Sani H . Postmenopausal osteoporosis and breast cancer: The biochemical links and beneficial effects of functional foods. Biomed Pharmacother. 2018; 107:571-582. DOI: 10.1016/j.biopha.2018.08.018. View

Baccaro L, Conde D, Costa-Paiva L, Pinto-Neto A . The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging. 2015; 10:583-91. PMC: 4374649. DOI: 10.2147/CIA.S54614. View

Kong L, Zuo K, Ma L . Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis. Pak J Med Sci. 2020; 36(7):1703-1707. PMC: 7674899. DOI: 10.12669/pjms.36.7.1964. View

10.

Ettinger B . Tibolone for prevention and treatment of postmenopausal osteoporosis. Maturitas. 2007; 57(1):35-8. DOI: 10.1016/j.maturitas.2007.02.008. View

11.

. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006; 13(3):340-67. DOI: 10.1097/01.gme.0000222475.93345.b3. View

12.

Eastell R, Rosen C, Black D, Cheung A, Murad M, Shoback D . Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019; 104(5):1595-1622. DOI: 10.1210/jc.2019-00221. View

13.

Miller P . Management of severe osteoporosis. Expert Opin Pharmacother. 2015; 17(4):473-88. DOI: 10.1517/14656566.2016.1124856. View

14.

de Medeiros S, Yamamoto M, Barbosa J . Abnormal bleeding during menopause hormone therapy: insights for clinical management. Clin Med Insights Womens Health. 2014; 6:13-24. PMC: 3941181. DOI: 10.4137/CMWH.S10483. View

15.

Cauley J, Black D, Boonen S, Cummings S, Mesenbrink P, Palermo L . Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. J Bone Miner Res. 2011; 26(5):984-92. PMC: 5104553. DOI: 10.1002/jbmr.292. View

16.

Liao R, Yu M, Jiang Y, Xia W . Management of osteoporosis with calcitriol in elderly Chinese patients: a systematic review. Clin Interv Aging. 2014; 9:515-26. PMC: 3974693. DOI: 10.2147/CIA.S40465. View

17.

Rizzoli R . Postmenopausal osteoporosis: Assessment and management. Best Pract Res Clin Endocrinol Metab. 2018; 32(5):739-757. DOI: 10.1016/j.beem.2018.09.005. View

18.

Lien Y, Madrasi K, Samant S, Kim M, Li F, Li L . Establishment of a Disease-Drug Trial Model for Postmenopausal Osteoporosis: A Zoledronic Acid Case Study. J Clin Pharmacol. 2020; 60 Suppl 2:S86-S102. DOI: 10.1002/jcph.1748. View

19.

Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen H . Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19(2):558-67. DOI: 10.1200/JCO.2001.19.2.558. View

20.

Anupama D, Norohna J, Acharya K, Ravishankar , George A . Effect of exercise on bone mineral density and quality of life among postmenopausal women with osteoporosis without fracture: A systematic review. Int J Orthop Trauma Nurs. 2020; 39:100796. DOI: 10.1016/j.ijotn.2020.100796. View